An advisory committee is not a listing

In April 2026 the Federal Register announced a July meeting of FDA’s Pharmacy Compounding Advisory Committee. The notice is 91 FR 20465. The docket is FDA-2025-N-6895. The Committee’s stated function is to provide advice and recommendations. That is the whole of the object: advice.

Advice is not a listing. A listing is a later regulatory act. Until FDA places a bulk substance on the 503A Bulks List through the process the statute describes, the substance is not on the list. A meeting notice does not do that work. A discussion does not do that work. A recommendation, if one is later recorded, still does not do that work.

What the notice actually scheduled

The April 16 notice set the meeting for July 23 and 24, 2026. The agenda was bulk drug substances nominated for inclusion on the section 503A Bulks List. July 23 covered BPC-157, KPV, TB-500, and MOTS-c, each as free base and acetate. July 24 covered emideltide (DSIP), Semax, and Epitalon, again as free base and acetate.

The notice also named uses FDA said it had reviewed for the discussion: ulcerative colitis for BPC-157; wound healing and inflammatory conditions for KPV; wound healing for TB-500; obesity and osteoporosis for MOTS-c; opioid withdrawal, chronic insomnia, and narcolepsy for emideltide; cerebral ischemia, migraine, and trigeminal neuralgia for Semax; insomnia for Epitalon. Those are the uses evaluated for an advisory discussion. They are not labelled indications, and they are not a finding that the substances belong on the list.

What 503A is, in the notice’s own terms

Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions under which a compounded human drug product may be exempt from certain manufacturing, labeling, and new-drug-approval requirements. One condition is the identity of the bulk substance. If there is no applicable USP or National Formulary monograph, and the substance is not a component of an approved drug, it must appear on a list developed by the Secretary through regulations: the 503A Bulks List.

The Committee was asked to discuss nominated substances in that frame. The notice does not add them to the list. It asks for advice about whether they should be considered for it.

What the meeting does not change

• It does not place the nominated substances on the 503A list.
• It does not approve a product or create a labelled use.
• It does not enlarge a trial or change an evidence grade.
• It is not a buying signal, and it is not a reason to treat a research compound as an approved medicine.

On Strand the agenda items that already have records are BPC-157, TB-500, MOTS-c, Semax, and Epithalon. Those records stay research until a later act changes the object. An advisory-committee discussion belongs in the regulatory notes. It does not move the status tag from research to approved, and it does not turn preclinical or limited human literature into a labelled medicine.

How to read a later vote, if one is posted

If FDA later posts a recommendation or a vote, read it as advice to the agency. A narrow recommendation to list a substance is still a recommendation. The list changes when the listing changes. Until then, the Federal Register notice is a meeting announcement, and the meeting is a discussion.

That is the whole distinction this page is for. The agenda is real. The list is a different document.